Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05233592 · ClinicalTrials.gov registry record
Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 21
- Enrollment target
NCT05233592: Completed study, sponsored by Johns Hopkins University.
NCT05233592 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05233592 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
Vaccines for COVID-19 are an essential part of combating the coronavirus pandemic. Vaccines "prime" the immune system against an invader (in this case the SARS-CoV-2 virus) by causing a temporary increased immune or inflammatory response. Inflammation can temporarily increase sugar levels and/or insulin requirements among patients with diabetes. The purpose of this study is to investigate whether the "booster" COVID-19 vaccine dose causes temporarily increased sugar levels and/or insulin dose requirements among patients with Type 1 Diabetes (T1D).
Primary Outcome
Mean glucose multiplied by total daily insulin dose.
Interventions
- DEVICE CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2023-04-04 |
What the finished NCT05233592 record still lists
NCT05233592 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CGM is the first listed.
NCT05233592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05233592 about?
NCT05233592 is a clinical study titled "Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes". Vaccines for COVID-19 are an essential part of combating the coronavirus pandemic. Vaccines "prime" the immune system against an invader (in this case the SARS-CoV-2 virus) by causing a temporary increased immune or inflammatory response. Inflammation can temporarily increase sugar levels and/or ins...
What is the current status of trial NCT05233592?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2022-03-08. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT05233592?
The interventions under investigation include: CGM (DEVICE).
Who is sponsoring clinical trial NCT05233592?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI